<DOC>
	<DOCNO>NCT00073047</DOCNO>
	<brief_summary>The purpose The PROSPECT Study evaluate investigational medication treatment moderate severe ulcerative colitis . This study conduct 38 clinical research center US , Canada , Belgium , open male female patient 12 year old . Participants study number visit research center five-month period . All study relate care medication provide qualified participant cost : include visit , examination , laboratory work .</brief_summary>
	<brief_title>Humanized Anti-IL-2 Receptor Monoclonal Antibody Moderate-to-severe Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<mesh_term>Digestive System Diseases</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Daclizumab</mesh_term>
	<criteria>Moderate severe active ulcerative colitis diagnose least 4 month . Mayo score 510 ( inclusive ) Not use investigational therapy 30 day prior screen No treatment monoclonal antibody therapy within 12 week screen No prior treatment daclizumab</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Ulcerative Colitis</keyword>
	<keyword>Inflammatory Bowel Disease</keyword>
	<keyword>Gastrointestinal</keyword>
	<keyword>Humanized Monoclonal antibody</keyword>
</DOC>